Skip to main content

Table 3 Overview of antispastic therapies and measures during the study

From: Erratum to: ‘Quality of life and costs of spasticity treatment in German stroke patients’

IncobotulinumtoxinA group:
Antispastic medications except BoNT/A, non-pharmacological therapies and aids
  First quarter (n = 108) Second quarter (n = 102) Third quarter (n = 99) Fourth quarter (n = 94)
Oral medication 31 (28.7 %) 23 (32.4 %) 20 (20.2 %) 18 (19.1 %)
Physical therapy 60 (55.6 %) 54 (52.9 %) 54 (54.5 %) 51 (54.3 %)
Occupational therapy 43 (39.8 %) 42 (41.2 %) 41 (41.4 %) 44 (46.8 %)
Speech therapy 10 (9.3 %) 8 (7.8 %) 8 (8.1 %) 9 (8.6 %)
Other therapies 3 (2.8 %) 6 (6.0 %) 4 (4.0 %) 4 (4.3 %)
Therapeutic aids 12 (11.0 %) 5 (5.7 %) - 1 (1.0 %)
Conventional therapy group:
Antispastic medications, non-pharmacological therapies and aids
  First quarter (n = 110) Second quarter (n = 98) Third quarter (n = 91) Fourth quarter (n = 84)
Oral medication 67 (60.9 %) 66 (67.3 %) 63 (69.2 %) 58 (69.0 %)
Physical therapy 68 (61.8 %) 59 (60.2 %) 54 (54.5 %) 52 (61.9 %)
Occupational therapy 15 (13.6 %) 11 (11.2 %) 11 (12.1 %) 8 (9.5 %)
Speech therapy 5 (4.6 %) 5 (5.1 %) 5 (5.5 %) 4 (4.8 %)
Other therapies 3 (2.7 %) 5 (5.1 %) - 1 (1.2 %)
Therapeutic aids 10 (11.0 %) 8 (8.2 %) 12 (13.2 %) 8 (9.5 %)